Hemophilic factor VIIIC1-and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure

被引:94
作者
Liu, ML
Shen, BW
Nakaya, S
Pratt, KP
Fujikawa, K
Davie, EW
Stoddard, BL
Thompson, AR
机构
[1] Univ Washington, Puget Sound Blood Ctr, Dept Med, Seattle, WA 98104 USA
[2] Univ Washington, Dept Biochem, Seattle, WA 98104 USA
[3] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
关键词
D O I
10.1182/blood.V96.3.979.015k42a_979_987
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Factor VIII C domains contain key binding sites for von Willebrand factor (VWF) and phospholipid membranes. Hemophilic patients were screened for factor VIII C-domain mutations to provide a well-characterized series. Mutated residues were localized to the high-resolution C2 structure and to a homology model of C1, Of 30 families found with mutations in the C domains, there were 14 missense changes, and 9 of these were novel, Of the missense mutations, 10 were associated with reduced VWF binding and 8 were at residues with surface-exposed side chains. Six of the 10 mutants had nearly equivalent factor VIII clotting activity and antigen level, suggesting that reduced vWF binding could cause hemophilia by reducing factor VIII stability in circulation. When the present series was combined with previously described mutations from an online international database, 11 C1 and C2 mutations in patients with mild or moderately severe hemophilia A were associated with antibody-inhibitor development in at least one affected individual. Of these substitutions, 6 occurred at surface-exposed residues. As further details of the C1 structure and its interface with C2 become available, and as binding studies are performed on the plasma of more patients with hemophilic C-domain mutations, prediction of surface binding sites should improve, allowing confirmation by site-specific mutagenesis of surface-exposed residues, (C) 2000 by The American Society of Hematology.
引用
收藏
页码:979 / 987
页数:9
相关论文
共 51 条
[1]   Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules [J].
Barrow, RT ;
Healey, JF ;
Gailani, D ;
Scandella, D ;
Lollar, P .
BLOOD, 2000, 95 (02) :564-568
[2]   The canine factor VIII cDNA and 5′ flanking sequence [J].
Cameron, C ;
Notley, C ;
Hoyle, S ;
McGlynn, L ;
Hough, C ;
Kamisue, S ;
Giles, A ;
Lillicrap, D .
THROMBOSIS AND HAEMOSTASIS, 1998, 79 (02) :317-322
[3]   The evaluation of factor VIII binding activity of von willebrand factor by means of an ELISA method - Significance and practical implications [J].
Casonato, A ;
Pontara, E ;
Zerbinati, P ;
Zucchetto, A ;
Girolami, A .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1998, 109 (03) :347-352
[4]   HETERODUPLEX SCREENING FOR MOLECULAR DEFECTS IN FACTOR-IX GENES FROM HEMOPHILIA-B FAMILIES [J].
CHEN, SH ;
SCHOOF, JM ;
WEINMANN, AF ;
THOMPSON, AR .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 89 (02) :409-412
[5]   SEQUENCE OF THE MURINE FACTOR-VIII CDNA [J].
ELDER, B ;
LAKICH, D ;
GITSCHIER, J .
GENOMICS, 1993, 16 (02) :374-379
[6]   A human alloantibody interferes with binding of factor IXa to the factor VIII light chain [J].
Fijnvandraat, K ;
Celie, PHN ;
Turenhout, EAM ;
ten Cate, JW ;
van Mourik, JA ;
Mertens, K ;
Peters, M ;
Voorberg, J .
BLOOD, 1998, 91 (07) :2347-2352
[7]  
FOSTER PA, 1988, J BIOL CHEM, V263, P5230
[8]  
Gale AJ, 2000, THROMB HAEMOSTASIS, V83, P78
[9]   MEMBRANE-BINDING PEPTIDE FROM THE C2 DOMAIN OF FACTOR-VIII FORMS AN AMPHIPATHIC STRUCTURE AS DETERMINED BY NMR-SPECTROSCOPY [J].
GILBERT, GE ;
BALEJA, JD .
BIOCHEMISTRY, 1995, 34 (09) :3022-3031
[10]   CHARACTERIZATION OF THE HUMAN FACTOR-VIII GENE [J].
GITSCHIER, J ;
WOOD, WI ;
GORALKA, TM ;
WION, KL ;
CHEN, EY ;
EATON, DH ;
VEHAR, GA ;
CAPON, DJ ;
LAWN, RM .
NATURE, 1984, 312 (5992) :326-330